Addex pockets $111M in successful IPO

Switzerland's Addex Pharmaceuticals raised $111 million in its IPO on Monday. The company priced its shares at 73 Swiss francs each, near the top if its range. Investors were apparently attracted by Addex's pipeline of therapeutics. ADX10059 has completed two mid-stage studies for gastroesophageal reflux disease and migraine while an antismoking vaccine is in Phase IIa and another therapy is in early clinical development for depression, anxiety and inflammatory pain. Addex also has eight preclinical drugs in development. Addex's shares rose to 75 francs this morning.

"This capital increase allows us to pursue our expansion strategy and continue building a sustainable pharmaceutical business around our allosteric modulator platform," said chief finance officer and co-founder Tim Dyer.

- checkout the AFX report on Addex

ALSO: Amsterdam Molecular Therapeutics says it's planning an IPO on the Amsterdam exchange. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.